NEU 9.30% $20.96 neuren pharmaceuticals limited

Ha... I just finished putting something together! There's been...

  1. 5,815 Posts.
    lightbulb Created with Sketch. 16665
    Ha... I just finished putting something together!

    There's been so much emotion and opinion today I thought I'd just stick with what I got from Acadia's Earnings Call. My one comment is that I'm personally not surprised by the price action today - this is how the game is played.

    • There’s currently 850 patients on Daybue.
    • Persistency rate at 7 months is 63%.
    • Compliance rate is 75-80%.
    • Current average patient weight is in the low 30kgs (v. 27kg used to estimate average pricing at time of launch).
    • Current average patient age is 16 years.
    • Zero drop-out rate in the patients who rolled over from the Lilac 2 trial.
    • Expected Q1 2024 sales of US$76-82m, reflecting closure of most Rett clinics in January with sales pulled forward into December 23 in anticipation.
    • Full FY expectation is US$370-420m, including the US$76-82m estimate for Q1.
    • Management sees ample opportunity to continue to grow sales. They expect Daybue sales to increase significantly both over 2024 and in the years to come.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$20.96
Change
-2.150(9.30%)
Mkt cap ! $2.676B
Open High Low Value Volume
$22.50 $22.70 $20.28 $24.29M 1.141M

Buyers (Bids)

No. Vol. Price($)
1 259 $20.95
 

Sellers (Offers)

Price($) Vol. No.
$20.98 1641 2
View Market Depth
Last trade - 16.10pm 29/05/2024 (20 minute delay) ?
Last
$21.07
  Change
-2.150 ( 9.39 %)
Open High Low Volume
$22.45 $22.67 $20.27 399615
Last updated 15.59pm 29/05/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.